Loading…
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
67pct
29d open
vs 6,526 other HR bills in the 114th — cohort avg 56d
Compassionate Access, Research Expansion, and Respect States Act of 2015 or the CARERS Act of 2015 Amends the Controlled Substances Act (CSA) to provide that control and enforcement provisions of such Act relating to marihuana shall not apply to any person acting in compliance with state law relating to the production, possession, distribution, dispensation, administration, laboratory testing, or delivery of medical marihuana. Transfers marihuana from schedule I to schedule II of the CSA. Excludes "cannabidiol" from the definition of "marihuana" and defines it separately as the substance cannabidiol, as derived from marihuana or the synthetic formulation, that contains not greater than 0.3% delta-9-tetrahydrocannabinol on a dry weight basis. Deems marihuana that is grown or possessed for purposes of making cannabidiol, in accordance with state law, to meet such concentration limitation unless the Attorney General determines that the state law is not reasonably calculated to comply with such definition. Prohibits a federal banking regulator from: (1) terminating or limiting the deposit insurance of a depository institution solely because it provides or has provided financial services to a marihuana-related legitimate business; or (2) prohibiting, penalizing, or otherwise discouraging a depository institution from providing financial services to a marihuana-related legitimate business. Prohibits a federal banking regulator from recommending, motivating, providing incentives, or encouraging a depository institution not to offer financial services to an individual, or to downgrade or cancel financial services offered to an individual, solely because: (1) the individual is a manufacturer of marihuana, (2) the individual is or later becomes an owner or operator of a marihuana-related legitimate business, or (3) the depository institution was not aware that the individual is the owner or operator of a marihuana-related legitimate business. Prohibits a federal banking regulator from taking any adverse or corrective supervisory action on a loan to an owner or operator of: (1) a marihuana-related legitimate business soley because the owner or operator is such a business, or (2) real estate or equipment that is leased to a marihuana-related legitimate business solely because it is leased to such a business. Provides depository institutions that provide financial services to a marihuana-related legitimate business protection under federal law from federal criminal prosecution or investigation, criminal penalties, and forfeiture of legal interest in collateral solely for providing financial services to such a business. Directs: (1) the Department of Health and Human Services to terminate the Public Health Service interdisciplinary review process described in the guidance entitled "Guidance on Procedures for the Provision of marihuana for Medical Research" (issued on May 21, 1999), and (2) the Drug Enforcement Administration to issue at least three licenses under CSA registration requirements to manufacture marihuana and marihuana-derivatives for research approved by the Food and Drug Administration. Directs the Department of Veterans Affairs (VA) to authorize VA health care providers to provide veterans with recommendations and opinions regarding participation in state marihuana programs.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (9)
Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Financial Services, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Sponsor introductory remarks on measure. (CR E385)
Introduced in House
Congress.gov source codes: 1000, Intro-H
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
Lobbying in support of H.R. 1013 - Regulate Marijuana Like Alcohol Act. Lobbying in support of H.R. 1014 - Marijuana Tax Revenue Act of 2015. Lobbying in support of H.R. 1940 - Respect State Marijuana Laws. Lobbying in support of S. 2237 - Ending Federal Marijuana Prohibition Act of 2015. Lobbying in support of S. 683 and H.R. 1538 - Compassionate Access, Research Expansion, and Respect States Act of 2015 General issues related to the cannabis industry and the need for elected officials on Capitol Hill to represent their state by urging the Obama administration to allow states to establish and carry out their own laws related to cannabis.
Client expense: $102,500 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · fourth_quarter · Medical/Disease Research/Clinical Labs
Increasing Parkinson's research at the NIH S.683 / H.R. 1538- Compassionate Access, Research Expansion, and Respect States Act of 2015, increasing access to medical marijuana, and enabling research into the medicinal properties of marijuana
Client expense: $18,810 · Firm income: Not reported
Government targets: Environmental Protection Agency (EPA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2016 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass amendments to various appropriations bills that would protect or benefit medical marijuana patients. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
S. 1965 Maintaining dignity and Eliminating unnecessary Restrictive Confinement of Youths Act of 2015 HR 2823 Protecting Youth from Solitary Confinement Act HR 1013 Regulate Marijuana like Alcohol Act of 2015 HR 1153 Asylum Reform and Board Protection Act of 2015 S. 683 Compassionate Access, Research Expansion, and Respect States Act of 2015 HR 1538 Compassionate Access, Research Expansion, and Respect States Act of 2015
Client expense: $36,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass amendments to various appropriations bills that would protect or benefit medical marijuana patients. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · third_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 1077: Advancing Breakthrough Devices for Patients Act of 2016 - Issues related to the biopharmaceutical industry S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S.2055: Medical Countermeasure Innovation Act of 2015 S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH S. 2912: Trickett Wendler Right to Try Act of 2016 - A bill to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes - Provisions related to use of unapproved medical products by patients with a terminal illness S. 3056: CREATES Act of 2016 - Provisions related to access to samples of prescription drugs S. 3239: RACE for Children Act - Provisions related to pediatric studies S. 3335: Fair Accountability and Innovative Research (FAIR) Drug Pricing Act - Provisions relating to transparency H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on medical research H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 or FAST Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3012: Right to Try Act of 2015 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 3250: DXM Abuse Prevention Act of 2015 H.R. 3299: The Strengthening Public Health Emergency Response Act of 2015 H.R. 3381: Childhood Cancer STAR Act - Provisions related to expanded access and other issues H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016 - Provisions related to opioids H.R. 5122: A bill to prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models H.R. 5858: The RACE for Children Act - Provisions related to pediatric studies H.R. 6043: Fair Accountability and Innovative Research (FAIR) Drug Pricing Act of 2016 - Provisions related to transparency H.R. 6174: Closing Loopholes for Orphan Drugs Act - Provisions relating to 340B discounts on orphan drugs Other: - Kids Innovative Drugs Act (draft) - Incentives for the development of pediatric oncology drugs - The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments - Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development - Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) - Incentives for the development of pediatric drugs - Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues - Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures - Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy - Proposed HRSA 340B program mega-guidance - Provisions related to 340B program - Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges - 340B Drug Discount Program policy issues - General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals - Prescription Drug User Fee Act (PDUFA) reauthorization - Biosimilar User Fee Act (BsUFA) reauthorization - Biologics Price Competition and Innovation Act (BPCIA) implementation issues - Biopharmaceutical and medical innovation policy issues - Drug development ecosystem policy issues - Drug cost and pricing policy issues - Expedited drug approval policy issues - Compassionate use policy issues - Biosimilar approval and reimbursement policy issues - Transparency policy issues - NIH Funding policy issues - Precision Medicine Initiative - Biomarker policy issues - Policy issues related to prescription drug abuse and secure disposal - Drug compounding policy issues - Prescription drug importation policy issues - Cancer Moonshot - Prescription drug take back policy issues - Clinical trial policy issues - Pediatric cancer policy issues - Cancer drug vial size policy issues - House Republican Health Proposal (A Better Way) - OTC Monograph Reform - Expanded access policy issues - Patient assistance program policy issues
2016 · second_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2016 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 800: Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act - Issues related to the biopharmaceutical industry S. 849: Advancing Research for Neurological Diseases Act of 2016 - Provisions related to research on neurological diseases S. 1077: Advancing Breakthrough Devices for Patients Act of 2016 - Issues related to the biopharmaceutical industry S. 1101: Medical Electronic Data Technology Enhancement for Consumers' Health Act - Provisions related to regulation of software S. 1455: Recovery Enhancement for Addiction Treatment Act - Provisions related to opioids S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1622: FDA Device Accountability Act of 2016 - Issues related to the biopharmaceutical industry S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2014: Next Generation Researchers Act - Provisions related to NIH promoting new research. S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016 - Provisions related to rare disease treatment S. 2055: Medical Countermeasure Innovation Act of 2016 - Provisions related to priority review vouchers S. 2256: Co-Prescribing Saves Lives Act of 2015 - Provisions related to co-prescribing of opioids and reversal agents S. 2388: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2015 - Provisions related to reciprocity of drug approvals S. 2511: Improving Health Information Technology Act - Provisions related to health information technology (HIT) S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2624: National Biomedical Research Act - Provisions related to mandatory funding for NIH and FDA S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH S. 2713: Advancing Precision Medicine Act of 2016 - Provisions related to data sharing and security S. 2742: Promoting Biomedical Research and Public Health for Patients Act - Issues related to the biopharmaceutical industry S. 2912: A bill to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes - Provisions related to use of unapproved medical products by patients with a terminal illness S. 3056: CREATES Act of 2016 - Provisions related to access to samples of prescription drugs H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on medical research H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3012: Right to Try Act of 2015 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 3250: DXM Abuse Prevention Act of 2015 - Issues related to prescription drug abuse H.R. 3381: Childhood Cancer STAR Act - Provisions related to expanded access and other issues H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016 - Provisions related to opioids H.R. 5127: Curb Opioid Abuse By Advancing Technology Act of 2016 - Provisions related to opioids Kids Innovative Drugs Act (draft) The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Drug Supply Chain Security Act policy issues Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges 340B Drug Discount Program policy issues General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biologics Price Competition and Innovation Act (BPCIA) implementation issues Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Expedited drug approval policy issues Compassionate use policy issues Biosimilar approval and reimbursement policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker policy issues Policy issues related to prescription drug abuse and secure disposal Drug compounding policy issues Prescription drug importation policy issues Cancer Moonshot Prescription drug take back policy issues Clinical trial policy issues Pediatric cancer policy issues Cancer drug vial size policy issues House Republican Health Proposal (A Better Way)
2016 · third_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 1077: Advancing Breakthrough Devices for Patients Act of 2016 - Issues related to the biopharmaceutical industry S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH S. 2912: Trickett Wendler Right to Try Act of 2016 - A bill to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes - Provisions related to use of unapproved medical products by patients with a terminal illness S. 3056: CREATES Act of 2016 - Provisions related to access to samples of prescription drugs S. 3239: RACE for Children Act - Provisions related to pediatric studies S. 3335: Fair Accountability and Innovative Research (FAIR) Drug Pricing Act - Provisions relating to transparency H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on medical research H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 or FAST Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3012: Right to Try Act of 2015 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 3381: Childhood Cancer STAR Act - Provisions related to expanded access and other issues H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016 - Provisions related to opioids H.R. 5122: A bill to prohibit further action on the proposed rule regarding testing of Medicare Part B prescription drug models H.R. 5858: The RACE for Children Act - Provisions related to pediatric studies H.R. 6043: Fair Accountability and Innovative Research (FAIR) Drug Pricing Act of 2016 - Provisions related to transparency H.R. 6174: Closing Loopholes for Orphan Drugs Act - Provisions relating to 340B discounts on orphan drugs Kids Innovative Drugs Act (draft) - Incentives for the development of pediatric oncology drugs The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) - Incentives for the development of pediatric drugs Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges 340B Drug Discount Program policy issues General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals Prescription Drug User Fee Act (PDUFA) reauthorization Biosimilar User Fee Act (BsUFA) reauthorization Biologics Price Competition and Innovation Act (BPCIA) implementation issues Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Expedited drug approval policy issues Compassionate use policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker policy issues Policy issues related to prescription drug abuse and secure disposal Drug compounding policy issues Prescription drug importation policy issues Cancer Moonshot Prescription drug take back policy issues Clinical trial policy issues Pediatric cancer policy issues Cancer drug vial size policy issues House Republican Health Proposal (A Better Way) Expanded access policy issues
2016 · third_quarter · Law Enforcement/Crime/Criminal Justice
Lobbying in support of H.R. 1013 - Regulate Marijuana Like Alcohol Act. Lobbying in support of H.R. 1014 - Marijuana Tax Revenue Act of 2015. Lobbying in support of H.R. 1940 - Respect State Marijuana Laws. Lobbying in support of S. 2237 - Ending Federal Marijuana Prohibition Act of 2015. Lobbying in support of S. 683 and H.R. 1538 - Compassionate Access, Research Expansion, and Respect States Act of 2015 General issues related to the cannabis industry and the need for elected officials on Capitol Hill to represent their state by urging the Obama administration to allow states to establish and carry out their own laws related to cannabis.
Client expense: $102,500 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · third_quarter · Law Enforcement/Crime/Criminal Justice
S. 1965 Maintaining Dignity and Eliminating unnecessary Restrictive Confinement of Youths Act of 2015 HR 2823 Protecting Youth from Solitary Confinement Act HR 1013 Regulate Marijuana like Alcohol Act of 2015 HR 1153 Asylum Reform and Board Protection Act of 2015 S. 683 Compassionate Access, Research Expansion, and Respect States Act of 2015 HR 1538 Compassionate Access, Research Expansion, and Respect States Act of 2015
Client expense: $64,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA), Veterans Affairs, Dept of (VA)
2016 · second_quarter · Law Enforcement/Crime/Criminal Justice
Lobbying in support of H.R. 1013 - Regulate Marijuana Like Alcohol Act. Lobbying in support of H.R. 1014 - Marijuana Tax Revenue Act of 2015. Lobbying in support of H.R. 1940 - Respect State Marijuana Laws. Lobbying in support of S. 2237 - Ending Federal Marijuana Prohibition Act of 2015. Lobbying in support of S. 683 and H.R. 1538 - Compassionate Access, Research Expansion, and Respect States Act of 2015 General issues related to the cannabis industry and the need for elected officials on Capitol Hill to represent their state by urging the Obama administration to allow states to establish and carry out their own laws related to cannabis.
Client expense: $112,500 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2016 · second_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 2055 - the Medical Countermeasure Innovation Act of 2015 S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to National Institutes of Health (NIH) funding and covered manufacturer supplemental fees S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2016 S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 800: Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act S. 849: Advancing Research for Neurological Diseases Act of 2016 - Provisions related to research on neurological diseases S. 1077: Advancing Breakthrough Devices for Patients Act of 2016 S. 1101: Medical Electronic Data Technology Enhancement for Consumers' Health Act - Provisions related to regulation of software S. 1455: Recovery Enhancement for Addiction Treatment Act - Provisions related to opioids S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1622: FDA Device Accountability Act of 2016 S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2014: Next Generation Researchers Act - Provisions related to NIH promoting new research. S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016 - Provisions related to rare disease treatment S. 2055: Medical Countermeasure Innovation Act of 2016 S. 2256: Co-Prescribing Saves Lives Act of 2015 - Provisions related to co-prescribing of opioids and reversal agents S. 2388: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2015 - Provisions related to reciprocity of drug approvals S. 2511: Improving Health Information Technology Act - Provisions related to health information technology (HIT) S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2624: National Biomedical Research Act - Provisions related to mandatory funding for NIH and FDA S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH S. 2713: Advancing Precision Medicine Act of 2016 - Provisions related to data sharing and security S. 2742: Promoting Biomedical Research and Public Health for Patients Act S. 2912: A bill to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes - Provisions related to use of unapproved medical products by patients with a terminal illness S. 3056: CREATES Act of 2016 - Provisions related to access to samples of prescription drugs H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3012: Right to Try Act of 2015 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 3250: DXM Abuse Prevention Act of 2015 HR. 3299 - the Strengthening Public Health Emergency Response Act of 2015 H.R. 3381: Childhood Cancer STAR Act - Provisions related to expanded access and other issues H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016 - Provisions related to opioids H.R. 5127: Curb Opioid Abuse By Advancing Technology Act of 2016 - Provisions related to opioids Other: - Kids Innovative Drugs Act (draft) - The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments - Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development - ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances - Drug Supply Chain Security Act policy issues - Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) - Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues - Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures - Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy - Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges - 340B Drug Discount Program policy issues - General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals - Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization - Biologics Price Competition and Innovation Act (BPCIA) implementation issues - Biopharmaceutical and medical innovation policy issues - Drug development ecosystem policy issues - Drug cost and pricing policy issues - Expedited drug approval policy issues - Compassionate use policy issues - Biosimilar approval and reimbursement policy issues - Transparency policy issues - NIH Funding policy issues - Precision Medicine Initiative - Policy issues related to prescription drug abuse and secure disposal - Drug compounding policy issues - Prescription drug importation policy issues - Cancer Moonshot - Prescription drug take back policy issues - Clinical trial policy issues - Pediatric cancer policy issues - Cancer drug vial sizes policy issues - House Republican Health Proposal (A Better Way)
2016 · second_quarter · Law Enforcement/Crime/Criminal Justice
H. 683 and HR 1538 to amend the Controlled Substance Act (CSA) regarding the federal regulation of cannibus for medical use.
Client expense: Not reported · Firm income: Not reported
2016 · second_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to National Institutes of Health (NIH) funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 480: National All Schedules Prescription Electronic Reporting Reauthorization Act of 2016 - Provisions related to the reauthorization of the national controlled substance monitoring program S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 800: Enhancing the Stature and Visibility of Medical Rehabilitation Research at the NIH Act - Issues related to the biopharmaceutical industry S. 849: Advancing Research for Neurological Diseases Act of 2016 - Provisions related to research on neurological diseases S. 1077: Advancing Breakthrough Devices for Patients Act of 2016 - Issues related to the biopharmaceutical industry S. 1101: Medical Electronic Data Technology Enhancement for Consumers' Health Act - Provisions related to regulation of software S. 1455: Recovery Enhancement for Addiction Treatment Act - Provisions related to opioids S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1622: FDA Device Accountability Act of 2016 - Issues related to the biopharmaceutical industry S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2014: Next Generation Researchers Act - Provisions related to NIH promoting new research. S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016 - Provisions related to rare disease treatment S. 2055: Medical Countermeasure Innovation Act of 2016 - Provisions related to priority review vouchers S. 2256: Co-Prescribing Saves Lives Act of 2015 - Provisions related to co-prescribing of opioids and reversal agents S. 2388: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2015 - Provisions related to reciprocity of drug approvals S. 2511: Improving Health Information Technology Act - Provisions related to health information technology (HIT) S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2624: National Biomedical Research Act - Provisions related to mandatory funding for NIH and FDA S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH S. 2713: Advancing Precision Medicine Act of 2016 - Provisions related to data sharing and security S. 2742: Promoting Biomedical Research and Public Health for Patients Act - Issues related to the biopharmaceutical industry S. 2912: A bill to authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes - Provisions related to use of unapproved medical products by patients with a terminal illness S. 3056: CREATES Act of 2016 - Provisions related to access to samples of prescription drugs H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on medical research H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3012: Right to Try Act of 2015 - Provisions related to use of unapproved medical products by patients with a terminal illness H.R. 3250: DXM Abuse Prevention Act of 2015 - Issues related to prescription drug abuse H.R. 3381: Childhood Cancer STAR Act - Provisions related to expanded access and other issues H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications H.R. 5046: Comprehensive Opioid Abuse Reduction Act of 2016 - Provisions related to opioids H.R. 5127: Curb Opioid Abuse By Advancing Technology Act of 2016 - Provisions related to opioids Kids Innovative Drugs Act (draft) The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Drug Supply Chain Security Act policy issues Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges 340B Drug Discount Program policy issues General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biologics Price Competition and Innovation Act (BPCIA) implementation issues Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Expedited drug approval policy issues Compassionate use policy issues Biosimilar approval and reimbursement policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker policy issues Policy issues related to prescription drug abuse and secure disposal Drug compounding policy issues Prescription drug importation policy issues Cancer Moonshot Prescription drug take back policy issues Clinical trial policy issues Pediatric cancer policy issues Cancer drug vial size policy issues House Republican Health Proposal (A Better Way)
2016 · second_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · second_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · second_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · second_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass amendments to various appropriations bills that would protect or benefit medical marijuana patients. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · second_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. Worked to introduce and pass various appropriations amendments that would similarly protect or benefit medical marijuana patients.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · first_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.R. 667 - the Veterans Equal Access Act. The language of this bill is contained within the CARERS Act and is supported by ASA.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · first_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · second_quarter · Law Enforcement/Crime/Criminal Justice
S. 1965 Maintaining Dignity and Eliminating unnecessary Restrictive Confinement of Youths Act of 2015 HR 2823 Protecting Youth from Solitary Confinement Act HR 1013 Regulate Marijuana like Alcohol Act of 2015 HR 1153 Asylum Reform and Board Protection Act of 2015 S. 683 Compassionate Access, Research Expansion, and Respect States Act of 2015 HR 1538 Compassionate Access, Research Expansion, and Respect States Act of 2015
Client expense: $52,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2016 · first_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to National Institutes of Health (NIH) funding and covered manufacturer supplemental fees S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016 - Provisions related to registration under the Controlled Substances Act (CSA) S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 683: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research S. 849: Advancing Research for Neurological Diseases Act of 2016 - Provisions related to research on neurological diseases S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) S. 1455: Recovery Enhancement for Addiction Treatment Act - Provisions related to opioids S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2014: Next Generation Researchers Act - Provisions related to NIH promoting new research. S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016 - Provisions related to rare disease treatment S. 2055 - the Medical Countermeasure Innovation Act of 2015 S. 2256: Co-Prescribing Saves Lives Act of 2015 - Provisions related to co-prescribing S. 2388: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2015 - Provisions related to reciprocity of drug approvals S. 2503: Preventing Superbugs and Protecting Patients Act - Provisions related to antibiotic development S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2624: National Biomedical Research Act - Provisions related to mandatory funding for NIH and FDA S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Provisions related to the study of regulatory challenges for the approval of complex generic drugs H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2745: Standard Merger and Acquisition Reviews Through Equal Rules Act of 2015; Motion to Recommit H.R. 2745 with Instructions - Provisions related to prescription drug costs H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing HR. 3299 - the Strengthening Public Health Emergency Response Act of 2015 H.R. 3537: Synthetic Drug Control Act of 2015 - Provisions related to amending the Controlled Substances Analogue Act and the legislative scheduling of molecules used in legitimate medical research H.R. 3762: Restoring Americans Healthcare Freedom Reconciliation Act of 2015 - Provisions related to amending and withdrawing funding from the Affordable Care Act H.R. 4365: Protecting Patient Access to Emergency Medications Act of 2016 - Provisions related to controlled substances H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Drug Supply Chain Security Act policy issues Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] Provisions related to 340B program Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program policy issues General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biologics Price Competition and Innovation Act (BPCIA) implementation issues Generic Drug User Fee Act (GDUFA) policy issues Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Expedited drug approval policy issues Compassionate use policy issues Biosimilar approval and reimbursement policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker policy issues Policy issues related to prescription drug abuse and secure disposal Antibiotics development policy issues Drug compounding policy issues Nomination of Robert Califf to FDA Commissioner Prescription drug importation policy issues Cancer Moonshot
2016 · first_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to National Institutes of Health (NIH) funding and covered manufacturer supplemental fees S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016 - Provisions related to registration under the Controlled Substances Act (CSA) S. 524: Comprehensive Addiction and Recovery Act of 2016 - Provisions related to opioids S. 683: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research S. 849: Advancing Research for Neurological Diseases Act of 2016 - Provisions related to research on neurological diseases S. 1128: Preserving Access to Orphan Drugs Act of 2013 - Provisions related to orphan drug tax (113th Congress) S. 1455: Recovery Enhancement for Addiction Treatment Act - Provisions related to opioids S. 1597: Patient-Focused Impact Assessment Act of 2016 - Provisions related to patient-focused drug development S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: Combination Product Regulatory Fairness Act of 2016 - Provisions related to improvements in the regulation of combination drug-device products S. 1878: Advancing Hope Act of 2016 - Provisions related to pediatric cancer and other pediatric diseases S. 2014: Next Generation Researchers Act - Provisions related to NIH promoting new research. S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016 - Provisions related to rare disease treatment S. 2256: Co-Prescribing Saves Lives Act of 2015 - Provisions related to co-prescribing of opioids and reversal agents S. 2388: Reciprocity Ensures Streamlined Use of Lifesaving Treatments Act of 2015 - Provisions related to reciprocity of drug approvals S. 2503: Preventing Superbugs and Protecting Patients Act - Provisions related to antibiotic development S. 2512: Adding Zika Virus to the FDA Priority Review Voucher Program Act - Provisions related to priority review vouchers S. 2615: Increasing Competition in Pharmaceuticals Act - Provisions related to FDA review of generic drugs and study on risk evaluation and mitigation strategies (REMS) program S. 2624: National Biomedical Research Act - Provisions related to mandatory funding for NIH and FDA S. 2680: Mental Health Reform Act of 2016 - Provisions related to mental health issues S. 2689: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments S. 2700: FDA and NIH Workforce Modernization Act - Provisions related to FDA and NIH H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States (CARERS) Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Provisions related to the study of regulatory challenges for the approval of complex generic drugs H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2745: Standard Merger and Acquisition Reviews Through Equal Rules Act of 2015; Motion to Recommit H.R. 2745 with Instructions - Provisions related to prescription drug costs H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 3537: Synthetic Drug Control Act of 2015 - Provisions related to amending the Controlled Substances Analogue Act and the legislative scheduling of molecules used in legitimate medical research H.R. 3762: Restoring Americans Healthcare Freedom Reconciliation Act of 2015 - Provisions related to amending and withdrawing funding from the Affordable Care Act H.R. 4365: Protecting Patient Access to Emergency Medications Act of 2016 - Provisions related to controlled substances H.R. 4762: REGROW Act - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments H.R. 4784: Lower Drug Costs Through Competition Act - Provisions related to generic drugs and priority review vouchers; REMS study; and tropical disease product applications The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Drug Supply Chain Security Act policy issues Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed rules [CMS-2390-P] Provisions related to 340B program Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program policy issues General FDA advocacy including sharing of truthful and non-misleading information about medicines with healthcare professionals Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biologics Price Competition and Innovation Act (BPCIA) implementation issues Generic Drug User Fee Act (GDUFA) policy issues Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Expedited drug approval policy issues Compassionate use policy issues Biosimilar approval and reimbursement policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker policy issues Policy issues related to prescription drug abuse and secure disposal Antibiotics development policy issues Drug compounding policy issues Nomination of Robert Califf to FDA Commissioner Prescription drug importation policy issues Cancer Moonshot
2016 · first_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.R. 667 - the Veterans Equal Access Act. The language of this bill is contained within the CARERS Act and is supported by ASA.
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2016 · first_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $90,000 · Firm income: Not reported
2016 · first_quarter · Law Enforcement/Crime/Criminal Justice
S. 1965 Maintaining dignity and Eliminating unnecessary Restrictive Confinement of Youths Act of 2015 HR 2823 Protecting Youth from Solitary Confinement Act HR 1013 Regulate Marijuana like Alcohol Act of 2015 HR 1153 Asylum Reform and Board Protection Act of 2015 S. 675 Record Expungement Designed to Enhance Employment Act of 2015 H.R. 1672 Record Expungement Designed to Enhance Employment Act of 2015 S. 683 Compassionate Access, Research Expansion, and Respect States Act of 2015 HR 1538 Compassionate Access, Research Expansion, and Respect States Act of 2015
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE, Substance Abuse & Mental Health Services Administration (SAMHSA)
2016 · first_quarter · Law Enforcement/Crime/Criminal Justice
H. 683 and HR 1538 to amend the Controlled Substance Act (CSA) regarding the federal regulation of cannibus for medical use.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
S. 683 / HR 1538: CARERS Act of 2015 S. 988 / H.R. 2062: Protecting Student Athletes from Concussions Act of 2015 S. 1475 / H.R. 2603: Saving Lives, Saving Costs Act S. 1073: Stopping Improper Payments to Deceased People Act H.R. 6: 21st Century Cures Act, Title 1, and Sections 1122, & 3021 H.R. 1600: Patients' Access to Treatments Act of 2015 H.R. 1589: Ensuring Childrens Access to Specialty Care Act H.R. 2373: Legitimate Use of Medicinal Marijuana Act Maintenance/expansion of Graduate Medical Education (GME); NIH Funding.
Client expense: $280,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Medicare Payment Advisory Commission (MedPAC), SENATE
2015 · fourth_quarter · Health Issues
S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 185: Promise for Antibiotics and Therapeutics for Health (PATH) Act - Provisions related to antibiotic drug approval for a limited population S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to National Institutes of Health (NIH) funding and covered manufacturer supplemental fees S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the Controlled Substances Act (CSA) S. 683: Compassionate Access, Research Expansion, and Respect States Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) S. 1790: Safe and Affordable Prescription Drugs Act of 2015 - Provisions related to importation S. 1767: The Combination Product Regulatory Fairness Act of 2015 - Provisions related to improvements in the regulation of combination drug-device products S. 2023: Prescription Drug Affordability Act of 2015 - Provisions related to importation S. 2055 - the Medical Countermeasure Innovation Act of 2015 H.R. 6: 21st Century Cures Act - Provisions related to biopharmaceutical discovery, development, delivery and transparency H.R. 471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the CSA H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to DEA scheduling H.R. 880: American Research and Competitiveness Act of 2015 - Provisions related to the research and development (R&D) tax credit H.R. 909: Andrea Sloan Compassionate Use Reform and Enhancement Act - Provisions related to expanded access H.R. 1321: Microbead-Free Waters Act of 2015 - Provisions related to bills applicability to prescription drugs H.R. 1455: Speeding Access to Already Approved Pharmaceuticals Act of 2015 - Provisions requiring FDA to expedite review of pharmaceuticals that are approved for marketing in the European Union H.R. 1537: Advancing Hope Act of 2015 - Provisions related to the pediatric rare disease voucher program H.R. 1538: Compassionate Access, Research Expansion, and Respect States Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 1576: Generic Complex Drugs Safety and Effectiveness for Patients Act of 2015 - Provisions related to the study of regulatory challenges for the approval of complex generic drugs H.R. 1635: Charlottes Web Medical Access Act of 2015 - Provisions related to regulation of marijuana and impact on legitimate medical research H.R. 2433: To amend the Federal Food, Drug, and Cosmetic Act with respect to enhancing combination products review - Provisions regarding the enhancement of combination products review H.R. 2479: To amend the Federal Food, Drug, and Cosmetic Act to provide for the issuance of up-to-date regulations and guidance applying to the dissemination by means of the Internet of information about medical products - Provisions related to dissemination of information about medical products H.R. 2536: Recovery Enhancement for Addiction Treatment Act - Provisions related to the treatment of drug addiction H.R. 2629: Antibiotic Development to Advance Patient Treatment Act - Provisions related to the approval of certain drugs for use in a limited population of patients H.R. 2805: Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 - Provisions related to the treatment of heroin and prescription opioid abuse H.R. 2820: Stem Cell Therapeutic and Research Reauthorization Act of 2015 - Provisions related to the reauthorization of the National Cord Blood Inventory program and the C.W. Bill Young Cell Transplantation Program H.R. 2841: Fair Access for Safe and Timely Generics Act of 2015 - Provisions related to requiring innovator pharmaceutical manufacturers to provide samples of risk evaluation and mitigation strategy (REMS) covered products to generic manufacturers for bioequivalence testing H.R. 2872: Opioid Addiction Treatment Modernization Act - Provisions related to the treatment of opioid addiction H.R. 3014: Medical Controlled Substances Transportation Act of 2015 - Provisions related to the transport of controlled substances by physicians in certain situations HR. 3299 - the Strengthening Public Health Emergency Response Act of 2015 H.R. 3537: Synthetic Drug Control Act of 2015 - Provisions related to amending the Controlled Substances Analogue Act and the legislative scheduling of molecules used in legitimate medical research H.R. 3680: Co-Prescribing to Reduce Overdoses Act of 2015 - Provisions related to the prescribing of opioid overdose reversal drug to at-risk patients H.R. 3762, Restoring Americans Healthcare Freedom Reconciliation Act - Provisions related to amending and withdrawing funding from the Affordable Care Act The Regenerative Medicine Regulatory Improvement Act (discussion draft) - Provisions related to creating a new regulatory pathway to speed the approval of certain stem cell treatments Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development ADF Incentive Act of 2015 (discussion draft) - Provisions providing manufacturers an incentive to develop abuse deterrent formulations (ADF) of controlled substances Breakpoints (discussion draft) - Provisions relating to the updating of breakpoint information for antibiotics on an FDA managed website Drug Supply Chain Security Act issues including the Charitable Donation Exemption Discussion of Reforms to the Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA) Food and Drug Administration Safety and Innovation Act (FDASIA) policy issues Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures Medicaid Managed Care, CHIP Delivered in Managed Care, Medicaid and CHIP Comprehensive Quality Strategies, and Revisions Related to Third Party Liability; Proposed Rules [CMS-2390-P] Provisions related to 340B program Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development and FDA policy Proposed HRSA 340B program mega-guidance - Provisions related to 340B program Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program policy issues General FDA advocacy Prescription Drug User Fee Act (PDUFA) negotiation and reauthorization Biopharmaceutical and medical innovation policy issues Drug development ecosystem policy issues Drug cost and pricing policy issues Transparency policy issues NIH Funding policy issues Precision Medicine Initiative Biomarker proposed legislation - Draft legislation related to developing a new approval pathway for biomarkers Rogue Internet Pharmacy policy issues Prescription drug abuse policy issues Drug compounding policy issues Nomination of Robert Califf to FDA Commissioner
2015 · fourth_quarter · Health Issues
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $10,000 · Firm income: Not reported
2015 · fourth_quarter · Alcohol and Drug Abuse
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $10,000 · Firm income: Not reported
2015 · fourth_quarter · Veterans
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $10,000 · Firm income: Not reported
2015 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. Would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.R. 667 - the Veterans Equal Access Act. The language of this bill is contained within the CARERS Act and is supported by ASA.
Client expense: $10,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
2015 · fourth_quarter · Banking
S. 683/H.R. 1538 - the Compassionate Access, Research Expansion, and Respect States (CARERS) Act, a medical marijuana bill that would protect patients, doctors, and others acting in accordance with their state medical marijuana laws from federal prosecution and interference. The bill would allow banks acting in accordance with state marijuana laws to have access to banking services, as currently, state-legal marijuana businesses must operate in a "cash only" environment. It would also expand health research for marijuana-based therapy, allow for the interstate transportation of low-THC/CBD-rich derivations of marijuana, reschedule marijuana to Sch. II under the CSA, advance and allow VA doctors to recommend medical marijuana veteran patients if allowed by state law. H.Amdt.130 "Veterans Equal Access Amendment" to H.R. 2029, (offered by Senator Daines in full committee markup in the Senate). States, "None of the funds made available by this Act may be used to implement, administer, or enforce Veterans Health Administration directive 2011-004 (or directive of the same substance) with respect to the prohibition on "VA providers from completing forms seeking recommendations or opinions regarding a Veteran's participation in a State marijuana program"." H.Amdt.332 to H.R. 2578, (offered by Senator Mikulski in full committee markup in the Senate): Amendment prohibits the use of funds in the bill to supersede State law in those States that have legalized the use of medical marijuana. Merkley marijuana banking amendment to FY16 Financial Services & General Government Appropriations Bill (H.R.2995 in House). To prohibit funds from being used to prohibit or penalize financial institutions that provide financial services to a certain persons in States where marijuana is legal for recreational or medicinal purposes.
Client expense: $10,000 · Firm income: Not reported
2015 · fourth_quarter · Law Enforcement/Crime/Criminal Justice
H. 683 and HR 1538 to amend the Controlled Substance Act (CSA) regarding the federal regulation of cannibus for medical use.
Client expense: Not reported · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
| Referred to |
| March 23, 2015 |
| Republican |
| CA |
| David Loebsack | Democratic | IA |
| David Scott | Democratic | GA |
| David Young | Republican | IA |
| Don Young | Republican | AK |
| Donald S. Beyer, Jr. | Democratic | VA |
| Duncan Hunter | Republican | CA |
| Earl Blumenauer | Democratic | OR |
| Ed Perlmutter | Democratic | CO |
| Eleanor Holmes Norton | Democratic | DC |
| Gerald E. Connolly | Democratic | VA |
| Hakeem S. Jeffries | Democratic | NY |
| Henry C. "Hank" Johnson, Jr. | Democratic | GA |
| Janice D. Schakowsky | Democratic | IL |
| Jerrold Nadler | Democratic | NY |
| John Conyers, Jr. | Democratic | MI |
| Joseph J. Heck | Republican | NV |
| Julia Brownley | Democratic | CA |
| Justin Amash | Libertarian | MI |
| Madeleine Z. Bordallo | Democratic | GU |
| Mark Sanford | Republican | SC |
| Michelle Lujan Grisham | Democratic | NM |
| Mick Mulvaney | Republican | SC |
| Mike Coffman | Republican | CO |
| Peter A. DeFazio | Democratic | OR |
| Peter J. Visclosky | Democratic | IN |
| Raúl M. Grijalva | Democratic | AZ |
| Richard L. Hanna | Republican | NY |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sean Patrick Maloney | Democratic | NY |
| Seth Moulton | Democratic | MA |
| Suzan K. DelBene | Democratic | WA |
| Ted Lieu | Democratic | CA |
| Theodore E. Deutch | Democratic | FL |
| Thomas Massie | Republican | KY |
| Tom McClintock | Republican | CA |
| Tom Rice | Republican | SC |
| Tulsi Gabbard | Democratic | HI |
| Walter B. Jones | Republican | NC |
| Zoe Lofgren | Democratic | CA |
| HR 1940 |
114th |
| Related bill |
Client expense: $640,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), Vice President of the U.S.
Client expense: $4,550,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Client expense: $4,130,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), Office of Management & Budget (OMB), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Client expense: $1,070,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
Client expense: $5,820,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Natl Security Council (NSC), Office of the Vice President of the United States, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Client expense: $1,490,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S.
Client expense: $5,950,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), Vice President of the U.S.
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Client expense: $380,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR), White House Office
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)
Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Office of Natl Drug Control Policy (NDCP), SENATE, Veterans Affairs, Dept of (VA)